X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (32640) 32640
Book Review (2873) 2873
Publication (1720) 1720
Newsletter (1288) 1288
Newspaper Article (181) 181
Conference Proceeding (55) 55
Book Chapter (51) 51
Magazine Article (45) 45
Dissertation (36) 36
Trade Publication Article (10) 10
Transcript (8) 8
Paper (3) 3
Book / eBook (1) 1
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (27962) 27962
humans (18567) 18567
dexamethasone (17580) 17580
male (15594) 15594
female (13921) 13921
animals (11363) 11363
dexamethasone - administration & dosage (9857) 9857
dexamethasone - pharmacology (7780) 7780
adult (7644) 7644
middle aged (7449) 7449
rats (5520) 5520
aged (5265) 5265
dexamethasone - therapeutic use (4762) 4762
treatment outcome (3717) 3717
oncology (3599) 3599
abridged index medicus (3598) 3598
steroids (3359) 3359
pharmacology & pharmacy (3032) 3032
mice (2944) 2944
corticosteroids (2831) 2831
antineoplastic combined chemotherapy protocols - therapeutic use (2779) 2779
hematology (2704) 2704
glucocorticoids (2638) 2638
research (2503) 2503
glucocorticoids - administration & dosage (2502) 2502
adolescent (2335) 2335
time factors (2301) 2301
endocrinology & metabolism (2287) 2287
care and treatment (2246) 2246
dose-response relationship, drug (2215) 2215
glucocorticoids - pharmacology (2204) 2204
analysis (2193) 2193
therapy (2186) 2186
multiple myeloma (2158) 2158
dexamethasone - adverse effects (2092) 2092
multiple myeloma - drug therapy (1993) 1993
chemotherapy (1967) 1967
dosage and administration (1860) 1860
pregnancy (1848) 1848
neurosciences (1830) 1830
hydrocortisone - blood (1805) 1805
drug therapy, combination (1795) 1795
expression (1706) 1706
cancer (1695) 1695
drug therapy (1695) 1695
child (1686) 1686
surgery (1662) 1662
inflammation (1604) 1604
prospective studies (1601) 1601
pediatrics (1582) 1582
aged, 80 and over (1569) 1569
bortezomib (1563) 1563
anti-inflammatory agents - administration & dosage (1538) 1538
medicine & public health (1537) 1537
retrospective studies (1500) 1500
health aspects (1483) 1483
rats, sprague-dawley (1454) 1454
central nervous system depressants (1368) 1368
drug administration schedule (1356) 1356
ophthalmology (1343) 1343
double-blind method (1316) 1316
follow-up studies (1309) 1309
anti-inflammatory agents - therapeutic use (1298) 1298
disease models, animal (1294) 1294
rats, wistar (1289) 1289
glucocorticoids - therapeutic use (1287) 1287
immunology (1269) 1269
antineoplastic combined chemotherapy protocols - adverse effects (1234) 1234
risk factors (1205) 1205
biochemistry & molecular biology (1194) 1194
children (1181) 1181
cells, cultured (1175) 1175
prevention (1173) 1173
child, preschool (1124) 1124
cells (1123) 1123
infant, newborn (1107) 1107
psychiatry (1063) 1063
anti-inflammatory agents - pharmacology (1049) 1049
cyclophosphamide - administration & dosage (1035) 1035
clinical trials (1027) 1027
drugs (1027) 1027
medicine, general & internal (1014) 1014
administration, oral (990) 990
antineoplastic combined chemotherapy protocols - administration & dosage (983) 983
double-blind (983) 983
doxorubicin - administration & dosage (981) 981
vincristine - administration & dosage (979) 979
cortisol (975) 975
young adult (936) 936
apoptosis (933) 933
physiological aspects (928) 928
thalidomide - administration & dosage (922) 922
cell biology (921) 921
administration, topical (913) 913
infant (896) 896
prognosis (894) 894
medical research (893) 893
clinical neurology (889) 889
recurrence (887) 887
survival (887) 887
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (32206) 32206
Japanese (397) 397
German (396) 396
French (279) 279
Chinese (229) 229
Russian (188) 188
Spanish (154) 154
Polish (88) 88
Italian (57) 57
Portuguese (50) 50
Czech (38) 38
Korean (23) 23
Dutch (21) 21
Hungarian (19) 19
Turkish (15) 15
Danish (12) 12
Persian (12) 12
Swedish (11) 11
Romanian (8) 8
Ukrainian (8) 8
Croatian (7) 7
Bulgarian (6) 6
Norwegian (6) 6
Serbian (5) 5
Hebrew (4) 4
Bosnian (2) 2
Finnish (2) 2
Arabic (1) 1
Indonesian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells | Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2014, Volume 165, Issue 4, pp. 534 - 544
The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [ HL ] after a... 
refractory disease | relapse | children | odgkin lymphoma | survival | Relapse | Children | Refractory disease | Survival | Hodgkin lymphoma | COMBINED-MODALITY THERAPY | PROGNOSTIC-FACTORS | RADIATION | CHEMOTHERAPY | TRIAL | FRENCH SOCIETY | DISEASE | SALVAGE THERAPY | RADIOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Procarbazine - administration & dosage | Prednisolone - adverse effects | Recurrence | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Follow-Up Studies | Humans | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Hodgkin Disease - surgery | Hodgkin Disease - mortality | Vincristine - administration & dosage | Child | Dacarbazine - administration & dosage | Dexamethasone - administration & dosage | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Bleomycin - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Ifosfamide - administration & dosage | Adolescent | Vincristine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Multicenter Studies as Topic | Hodgkin Disease - drug therapy | Retrospective Studies | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Chlorambucil - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Ifosfamide - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Clinical Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Carmustine - administration & dosage | Patient outcomes | Diseases | Index Medicus
Journal Article
Journal Article
Blood, ISSN 0006-4971, 01/2013, Volume 121, Issue 1, pp. 48 - 53
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 7, pp. 1214 - 1221
From 2001 to 2011, 122 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia were treated with chemotherapy + imatinib (n... 
ADULT PATIENTS | HYPER-CVAD | GENE REARRANGEMENTS | STANDARD-RISK | QUANTIFICATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | FLOW-CYTOMETRY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | CLINICAL-SIGNIFICANCE | Piperazines - administration & dosage | Cyclophosphamide - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Thiazoles - administration & dosage | Neoplasm Recurrence, Local - mortality | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Benzamides - administration & dosage | Flow Cytometry | Neoplasm, Residual - diagnosis | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Neoplasm, Residual - mortality | Philadelphia Chromosome | Real-Time Polymerase Chain Reaction | Doxorubicin - administration & dosage | Dasatinib | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Pyrimidines - administration & dosage | RNA, Messenger - genetics | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Cytarabine - administration & dosage | Neoplasm, Residual - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | Immunoglobulin Heavy Chains - genetics | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
British journal of cancer, ISSN 0007-0920, 2014, Volume 111, Issue 6, pp. 1072 - 1079
Background: Central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is a devastating complication; the optimal prophylactic strategy... 
cytarabine | INTERMEDIATE-GRADE | FOLLOW-UP | diffuse large B-cell lymphoma | methotrexate intrathecal | CHEMOTHERAPY | central nervous system | RELAPSE | central nervous system prophylaxis | ONCOLOGY | STANDARD CHOP | NON-HODGKINS-LYMPHOMA | CNS PROPHYLAXIS | AGGRESSIVE LYMPHOMA | RITUXIMAB ERA | ELDERLY-PATIENTS | Recurrence | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Central Nervous System Neoplasms - secondary | Young Adult | Central Nervous System Neoplasms - prevention & control | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Acute Kidney Injury - chemically induced | Retrospective Studies | Doxorubicin - administration & dosage | Injections, Spinal | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Rituximab | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Administration, Intravenous | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Aged | Index Medicus | intrathecal | methotrexate | Clinical Study
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2009 - 2017
Summary Background Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | IDARUBICIN | THERAPY | DOSE ARA-C | PEDIATRIC-PATIENTS | SENSITIVITY | RISK | CHILDHOOD LEUKEMIA | EXPERIENCE | ACCELERATED APPROVAL | ONCOLOGY GROUP | Recurrence | Cyclophosphamide - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Female | Leukocyte Count | Child | Idarubicin - therapeutic use | Mitoxantrone - therapeutic use | Dexamethasone - administration & dosage | Risk Assessment | Kaplan-Meier Estimate | Mercaptopurine - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | United Kingdom | Vidarabine - analogs & derivatives | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Vidarabine - administration & dosage | Complications and side effects | Dosage and administration | Acute lymphocytic leukemia | Drug therapy | Patient outcomes | Mitoxantrone hydrochloride | Studies | Design | Medical research | Chemotherapy | Cytogenetics | Cancer therapies | Data bases | Cancer | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 6/2013, Volume 21, Issue 6, pp. 1655 - 1663
Olanzapine has been shown to be a safe and effective agent for the prevention of chemotherapy-induced nausea and vomiting (CINV). Olanzapine may also be an... 
Breakthrough nausea and emesis | Pain Medicine | Chemotherapy | Nursing | Rehabilitation Medicine | Olanzapine | Medicine & Public Health | Oncology | Metoclopramide | Nursing Management/Nursing Research | DEXAMETHASONE | PREVENTION | APREPITANT | ANTIEMETIC ACTIVITY | CANCER-PATIENTS | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | REHABILITATION | PALONOSETRON | QUALITY-OF-LIFE | DELAYED NAUSEA | CISPLATIN-INDUCED EMESIS | Cyclophosphamide - administration & dosage | Isoquinolines - adverse effects | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Dexamethasone - adverse effects | Male | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Quinuclidines - administration & dosage | Cisplatin - administration & dosage | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Antiemetics - adverse effects | Female | Nausea - drug therapy | Vomiting - prevention & control | Quinuclidines - adverse effects | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Morpholines - administration & dosage | Metoclopramide - administration & dosage | Vomiting - drug therapy | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Metoclopramide - adverse effects | Cisplatin - adverse effects | Benzodiazepines - administration & dosage | Aged | Benzodiazepines - adverse effects | Isoquinolines - administration & dosage | Doxorubicin - adverse effects | Care and treatment | Cyclophosphamide | Anthracyclines | Dexamethasone | Nausea | Cancer | Side effects | Drug therapy | Vomiting | Index Medicus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 6/2011, Volume 52, Issue 11, pp. 1374 - 1383
Background. The optimal time to initiate antiretroviral therapy (ART) in human immunodeficiency virus (HIV)—associated tuberculous meningitis is unknown.... 
Statistical median | HIV/AIDS | Antiretrovirals | Art therapy | Meningeal tuberculosis | HIV | Mortality | Random allocation | AIDS | Arts | HIV 1 | MORTALITY | SURVIVAL | THAILAND | INFECTIOUS DISEASES | HIV-INFECTION | ERA | ADOLESCENTS | CLINICAL-TRIALS | ADULTS | RISK | MICROBIOLOGY | IMMUNOLOGY | Lamivudine - administration & dosage | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Time Factors | Adult | Anti-Inflammatory Agents - administration & dosage | Female | HIV Infections - mortality | Antiretroviral Therapy, Highly Active - methods | Tuberculosis, Meningeal - mortality | Placebos - administration & dosage | Dexamethasone - administration & dosage | Tuberculosis, Meningeal - drug therapy | Benzoxazines - administration & dosage | Double-Blind Method | Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage | Anti-HIV Agents - adverse effects | Treatment Outcome | Tuberculosis, Meningeal - complications | HIV Infections - complications | Antitubercular Agents - administration & dosage | HIV Infections - drug therapy | Antiviral agents | Care and treatment | Patient outcomes | Dosage and administration | Drug therapy | Health aspects | HIV infection | Comorbid patients | Tuberculous meningitis | Clinical trials | Antiretroviral drugs | Meningitis | Human immunodeficiency virus--HIV | Risk assessment | Medical treatment | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 12/2015, Volume 121, Issue 23, pp. 4158 - 4164
Durable remissions and long‐term survival can be achieved with a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome‐positive... 
dasatinib | acute lymphoblastic leukemia | chemotherapy | combination | Philadelphia chromosome | ADULT PATIENTS | ACUTE LYMPHOCYTIC-LEUKEMIA | REGIMEN | HYPER-CVAD | PONATINIB | THERAPY | ONCOLOGY | IMATINIB | MRD | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Methotrexate - therapeutic use | Cyclophosphamide - therapeutic use | Neoplasm, Residual | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Philadelphia Chromosome | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Dasatinib - therapeutic use | Treatment Outcome | Cytarabine - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Dexamethasone - therapeutic use | Dasatinib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - therapeutic use | Methotrexate - administration & dosage | Aged | Dasatinib | Chemotherapy | Usage | Care and treatment | Lymphocytic leukemia | Stem cells | Dosage and administration | Transplantation | Diagnosis | Cancer | Index Medicus | Abridged Index Medicus
Journal Article